Indian Neurotherapy-Mediated Reduction of Hyper C-Reactive Protein (CRP) in a Patient with Arthritis: A Case Study

Abstract

C-Reactive Protein (CRP) is a sensitive biomarker of systemic inflammation and is commonly elevated in patients with inflammatory arthritis. Elevated CRP levels are often associated with joint pain, swelling, stiffness, and reduced mobility. This case study evaluates the clinical and laboratory changes observed in a patient with Hyper-CRP-associated arthritis following Indian Neurotherapy combined with lifestyle modification. The patient received 280 Indian Neurotherapy (INT) sessions over approximately 15 months (April 2025-July 2026) at a Neurotherapy and Wellness Centre, Yamunanagar, following a baseline CRP assessment in March 2025. Treatment protocols included stimulation of inflammation- and metabolism-regulatory points (Pancreas, Gall Bladder, Liver, Parkhoo) with progressive formula modifications. Clinical symptoms and serial serum CRP levels were monitored throughout follow-up. The patient completed 280 Indian Neurotherapy sessions over approximately 15 months. During follow-up, CRP showed a consistent downward trend, decreasing from 12.65 mg/L (baseline) to 12.39 mg/L (June 2025), 8.74 mg/L (October 2025), 6.44 mg/L (April 2026), and 5.68 mg/L (July 2026). This represented an overall reduction of approximately 55.1% from baseline. This single-patient case study demonstrates that Indian Neurotherapy, when combined with dietary modification and regular walking, was associated with an overall reduction in serum CRP and improvement in the patient's clinical symptoms.